塞德斯医疗于6月14日公布,其研发的巴佐伏单抗在针对慢性自发性荨麻疹患者的二期临床研究中,成功达到了主要疗效终点。同时,该公司在欧洲过敏与临床免疫学学会年会上展示了该药物的长期数据,结果显示,患者在停止治疗后,其血管性水肿症状仍能获得持续改善。
塞德斯医疗于6月14日公布,其研发的巴佐伏单抗在针对慢性自发性荨麻疹患者的二期临床研究中,成功达到了主要疗效终点。同时,该公司在欧洲过敏与临床免疫学学会年会上展示了该药物的长期数据,结果显示,患者在停止治疗后,其血管性水肿症状仍能获得持续改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.